General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-14 | 2024-03 | -0.43 | -0.4 | 0.03 | 6.98% |
2024-03-18 | 2023-12 | -0.45 | N/A | N/A | N/A |
2024-03-18 | 2023-12 | -0.45 | -0.4 | 0.05 | 11.11% |
2023-11-08 | 2023-09 | -0.47 | -0.39 | 0.08 | 17.02% |
2023-11-08 | 2023-09 | -0.47 | N/A | N/A | N/A |
2023-08-09 | 2023-06 | -0.51 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-13 | Chardan Capital | Upgrade | Buy | Buy |
2023-08-10 | Canaccord Genuity | Upgrade | Buy | Buy |
2023-08-09 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-11 | Chardan Capital | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-02-22 | ALI FARAZ | Chief Executive Officer | 198.08K | Stock Award(Grant) |
2022-11-16 | CASDIN ELI | Director | 0.00 | Purchase |
2021-08-02 | CASDIN PARTNERS MASTER FUND, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2021-08-02 | COLUMN GROUP II, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
2024-02-11 | COLUMN GROUP III GP, L.P | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2024-02-11 | GOEDDEL DAVID V | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Column Group LLC | 9.40M | 55.18M | 13.85% |
2023-06-29 | Casdin Capital, LLC | 6.38M | 37.46M | 9.40% |
2023-06-29 | RA Capital Management, L.P. | 6.07M | 35.62M | 8.94% |
2023-06-29 | Price (T.Rowe) Associates Inc | 4.47M | 26.24M | 6.59% |
2023-06-29 | FMR, LLC | 3.75M | 22.04M | 5.53% |
2023-06-29 | Blackrock Inc. | 3.64M | 21.34M | 5.36% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Price (T.Rowe) New Horizons Fund | 2.43M | 14.26M | 3.58% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 1.48M | 5.72M | 2.18% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.28M | 7.53M | 1.89% |
2023-06-29 | Price (T.Rowe) Health Sciences Fund | 1.18M | 6.93M | 1.74% |
2023-08-30 | iShares Russell 2000 ETF | 1.03M | 3.99M | 1.52% |
2023-06-29 | Price (T.Rowe) Small-Cap Value Fund | 883.58K | 5.19M | 1.30% |
ZACKS RATES $TNYA a 2, looking bullish with room to grow!
LOW WILSON Getting Lower. What a hack! As if his loose bets would have more influence than the streets!!
Shorts haven’t learned. They are in for a beating $TNYA $SAVA
Funny how the dogs bark louder when there is a feeding! Yes, dogs…. This Stock has great 5x potential now that there is blood in the water… Thank you shorts for the gift!
Getting real close to massive reload.
Visionary Education Technology: Registration statement for securities of certain Canadian issuers (Amendment)
SEC announcement
·
03/25/2022 08:22
Visionary Education Technology(VEDU.US)
0.190
+13.70%
This announcement includes 6 separate documents:
Doc 1: View Original
Doc 2: View Original
Doc 3: View Origina
Getting more and more wound down, tension is building, a bounce is sure to happen soon…
Nice Try!!!
"Tenaya enters 2023 well capitalized and with meaningful milestones ahead," said Faraz Ali, Chief Executive Officer of Tenaya. "This year, we look forward to beginning clinical testing of our lead gene therapy candidate, TN-201, sharing data from our first-in-human clinical trial of TN-301, and submitting an IND for our TN-401 gene therapy candidate, as well as presenting additional data detailing insights on current pipeline candidates and emerging platform innovations."